Research and Markets: Global Neutropenia Clinical Trials Review Report - H2 2013
Research and Markets: Prostate Cancer Market to Almost Double by 2019 as New Treatments Emerge
ImmunoGen, Inc. Announces Approval of Roche’s Kadcyla® in the European Union
Rising interest rates have taken their toll, but as the Fed delays dialing back on stimulus, investors are poised to recapture some of their losses.
While a majority of our top fund managers are outperforming this year, five of them truly stand out from the rest given their ability to outperform the market over all time periods.
Morningstar StockInvestor editor Matt Coffina discusses recent additions to the Wide Moat Focus Index.
Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...
The broad stock runup in the first half of 2013 was a boon to ClearBridge Aggressive Growth, and comanager Evan Bauman says that the fund is well-positioned for the market going forward.
Aratana Therapeutics Strengthens Executive Management Team to Support Growth and Commercialization Initiatives